Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder

BMC Neuroscience

Volumn 2, Issue , 2001, Pages

  Ferris, Craig F ^a   Rasmussen, Mads F ^b   Messenger, Tara ^a   Koppel, Gary ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BUTLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; BUFFER; CLOMIPRAMINE; DESIPRAMINE; DIMETHYL SULFOXIDE; DRUG VEHICLE; FLUOXETINE; PENTOBARBITAL; SODIUM CHLORIDE; ADRENERGIC RECEPTOR AFFECTING AGENT; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; GROOMING; HAMSTER; MALE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; AGGRESSION; ANIMAL; DRUG EFFECT; GENETICS; HAIR; HYPOTHALAMUS; METABOLISM; MICROINJECTION; PHYSIOLOGY; PIGMENTATION;

ADRENERGIC UPTAKE INHIBITORS; AGGRESSION; ANIMALS; ARGININE VASOPRESSIN; BEHAVIOR, ANIMAL; CLOMIPRAMINE; CRICETINAE; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; GROOMING; HAIR; HYPOTHALAMUS; MALE; MICROINJECTIONS; OBSESSIVE-COMPULSIVE DISORDER; PIGMENTATION; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0035789594     PISSN: 14712202     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2202-2-10     Document Type: Article

References (39)

1. Ferris CF, Albers HE, Wesolowski SM, Goldman BD, Leeman SE: Vasopressin injected into the hypothalamus triggers a stereotypic behavior in golden hamsters. Science 1984, 224:521-523
2. Albers HE, Ferris CF: Behavioral effects of vasopressin and oxytocin within the medial preoptic area of the golden hamster. Regal Peptides 1985, 12:257-260
3. Johnston RE: Communication. In: The Hamster: Reproduction and Behavior. (Edited by Siege1HI), New York, Plenum Press 1985 121-154
4. Albers HE, Pollock J, Simmons WH, Ferris CF: A V1l-like receptor mediates vasopressin-induced flank marking behavior in hamster hypothalamus. J Neurosci 1986, 6:2085-2089
5. Ferris CF, Singer EA, Meenan DM, Albers HE: Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists. Eur J Pharmacol 1988, 154:153-159
6. Ferris CF: Vasopressin and social behaviors in the golden hamster. In: Proceedings of the Third International Vasopressin Conference (Edited by Jard S, Jamison, R) Colloque INSERM/John Libbey Eurotext Ltd. 1991, 208:185-193
7. Fehm-Wolfsdorf G, Bacholz G, Born J, Voight K, Fehm HL: Vasopressin but not oxytocin enhances cortical arousal: an integrative hypothesis on the behavioral effects of neurohypophyseal hormones. Psychopharmacology (Berp) 1988, 94:496-500
8. Cooper KE, Kasting NW, Lederis K, Veale WL: Evidence supporting a role for endogenous vasopressin in natural suppression of fever in the sheep. J Physiol 1979, 205:33-45
9. Pittman QJ, Lawrence D, Mclean L: Central effects of arginine vasopressin on blood pressure in rats. Endocrinology 1982, 110:1058-1060
10. Ferris CF, Stolberg T, Delville Y: Serotonin regulation of aggressive behavior in male golden hamsters Mesocricetus auratus). Behav Neurosci 1999, 113:804-815
11. Ferris CF, Melloni RH Jr, Perry KW, Fuller RW, Koppel G, Delville Y: Vasopressin/serotonin interaction in the anterior hypothalamus control aggressive behavior in golden hamsters. J Neurosci 1997, 17:4331-4340
12. De Wied D: Long term effect of vasopressin on the maintenance of a conditioned avoidance response in rats. Nature 1971, 232:58-60
13. Caldwell JD, Drago F, Prange AJ Jr, Pedersen CA: A comparison of grooming behavior potencies of neurohypophyseal nonapeptides. Regul Peptides 1986, 14:261-271
14. Delanoy RL, Dunn AJ, Tintner R: Behavioral responses to intracerebroventricularly administered neurohypophyseal peptides in mice. Horm Behav 1978, 11:348-362
15. Gold PW, Kaye W, Robertson G, Ebert M: Abnormalities in plasma and cerebrospinal fluid arginine vasopressin in patients with anorexia nervosa. N Engl J Med 1983, 308:1117-1123
16. Altemus M, Pigott T, Kalogeras KT, Demitrack M, Dubbert B, Murphy DL, Gold PW: Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessivecompulsive disorder. Arch Gen Psychiatry 1992, 49:9-20
17. Demitrack MA, Kalogeras K, Altemus M, Pigott TA, Listwak SJ, Gold PW: Plasma and cerebrospinal fluid measures of arginine vasopressin in patients with bulimia nervosa and in healthy subjects. J Clin Endocrinol Metab 1992, 74:1277-1283
18. Swedo SE, Leonard HL, Kruesi MI, Rettew DC, Listwak SI, Berrenttini W, Stipetic M, Hamburger S, Gold PW, Potter WZ, et al: Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49:29-36
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press 1994
20. Goodman WK, McDougle CJ, Price LH: Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 1992, 53:29-37
21. Hamberger B, Tuck JR: Effect of tricyclic antidepressants on the uptake of noradrenaline and 5-hydroxy-tryptamine by rat brain slices incubated in buffer of human plasma. Eur J Clin Pharmacol 1975, 5:229-235
22. Stark P, Fuller RW, Wong DT: The pharmacological profile of fluoxetine. J Clin Psychiatry 1985, 46:7-13
23. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995, 52:53-60
24. Richelson E, Pfenning M: Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984, 104:277-286
25. Rapoport JL, Ryland DH, Kriete M: Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49:517-521
26. Zohar J, Insel TR: Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987, 22:667-687
27. Swedo SE, Leonard HL, Rapoport JL, Lenane M, Cheslow D, Goldberger E: A double-blind comparison of Chlomipramine and desipramine in the treatment of trichotillomania (hair pulling) N Engl J Med 1989, 321:497-501
28. Insel TR, Winslow J: Neurobiology of obsessive-compulsive disorder. In: Obsessive-Compulsive Disorders: Theory and Management (Edited by Jenike M, Baer L, Minichiello W), 2nd ed. St Louis: Mosby-Year Book 1990 118-131
29. Stein DL, Shoulberg N, Helton K, Hollander E: The neuroethological approach to obsessive-compulsive disorder. Comprehensive Psychiatry 1992, 33:274-281
30. The Clomipramine Collaborative Study Group: Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991, 48:730-738
31. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ: A double-blind, placebo-controlled study of fluoxetine in patients with DSM-II-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993, 3:143-152
32. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994, 51:559-567
33. Blier P, de Montigny C, Chaput Y: Modification of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987, 7:24S-35S
34. Mongeau R, Blier P, de Montigny C: The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments. Brain Res Rev 1997, 23:145-195
35. Insel TR, Mueller EA, Alterman I, Linnoila , Murphy DL: Obsessivecompulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985, 20:1174-1188
36. Altemus M, Cizza G, Gold PW: Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res 1992, 593:311-313
37. Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, Anderson GM, Riddle MA, McDougle CJ, Barr LC, et al: The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinoly 1994, 19:723-749
38. Grindlinger H, Ramsey E: Compulsive feather picking in birds. Arch Gen Psychiatry 1991, 48:857
39. Altemus M, Glowa JR, Galliven E, Leong Y-M, Murphy DL: Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav 1996, 53:123-131.